Search Results - "Bujanda, L."

Mechanisms of Resistance to Chemotherapy in Gastric Cancer by Marin, J J G, Al-Abdulla, R, Lozano, E, Briz, O, Bujanda, L, Banales, J M, Macias, R I R

“…Although surgical resection is the standard curative therapy for gastric cancer, these tumors are often diagnosed at an advanced stage, when surgery is not…”
Get more information

Peptic Ulcer Bleeding Risk. The Role of Helicobacter Pylori Infection in NSAID/Low-Dose Aspirin Users by Sostres, C, Carrera-Lasfuentes, P, Benito, R, Roncales, P, Arruebo, M, Arroyo, M T, Bujanda, L, García-Rodríguez, L A, Lanas, A

“…Helicobacter pylori (H. pylori) infection and NSAID/low-dose aspirin (ASA) use are associated with peptic ulcer disease. The risk of peptic ulcer bleeding…”
Get full text

Resveratrol attenuates steatosis in obese Zucker rats by decreasing fatty acid availability and reducing oxidative stress by Gómez-Zorita, S., Fernández-Quintela, A., Macarulla, M. T., Aguirre, L., Hijona, E., Bujanda, L., Milagro, F., Martínez, J. A., Portillo, M. P.

“…Non-alcoholic fatty liver disease (NAFLD) is one of the most common manifestations of chronic liver disease worldwide. The aim of the present study was to…”
Get full text

SOX2 promotes dedifferentiation and imparts stem cell-like features to pancreatic cancer cells by Herreros-Villanueva, M, Zhang, J-S, Koenig, A, Abel, E V, Smyrk, T C, Bamlet, W R, de Narvajas, A A-M, Gomez, T S, Simeone, D M, Bujanda, L, Billadeau, D D

“…SOX2 (Sex-determining region Y (SRY)-Box2) has important functions during embryonic development and is involved in cancer stem cell (CSC) maintenance, in which…”
Get full text

Differential effects of FXR or TGR5 activation in cholangiocarcinoma progression by Erice, O., Labiano, I., Arbelaiz, A., Santos-Laso, A., Munoz-Garrido, P., Jimenez-Agüero, R., Olaizola, P., Caro-Maldonado, A., Martín-Martín, N., Carracedo, A., Lozano, E., Marin, J.J., O'Rourke, C.J., Andersen, J.B., Llop, J., Gómez-Vallejo, V., Padro, D., Martin, A., Marzioni, M., Adorini, L., Trauner, M., Bujanda, L., Perugorria, M.J., Banales, J.M.

“…Cholangiocarcinoma (CCA) is an aggressive tumor type affecting cholangiocytes. CCAs frequently arise under certain cholestatic liver conditions. Intrahepatic…”
Get full text

Exome sequencing of early-onset patients supports genetic heterogeneity in colorectal cancer by Fernández-Rozadilla, C., Álvarez-Barona, M., Quintana, I., López-Novo, A., Amigo, J., Cameselle-Teijeiro, J. M., Roman, E., Gonzalez, D., Llor, X., Bujanda, L., Bessa, X., Jover, R., Balaguer, F., Castells, A., Castellví-Bel, S., Capellá, G., Carracedo, A., Valle, L., Ruiz-Ponte, Clara

“…Colorectal cancer (CRC) is a complex disease that can be caused by a spectrum of genetic variants ranging from low to high penetrance changes, that interact…”
Get full text

MicroRNAs and extracellular vesicles in cholangiopathies by Olaizola, P., Lee-Law, P.Y., Arbelaiz, A., Lapitz, A., Perugorria, M.J., Bujanda, L., Banales, J.M.

“…Cholangiopathies encompass a heterogeneous group of disorders affecting biliary epithelial cells (i.e. cholangiocytes). Early diagnosis, prognosis and…”
Get full text

Extracolonic Cancer in Inflammatory Bowel Disease: Data from the GETECCU Eneida Registry by Chaparro, María, Ramas, M, Benítez, J M, López-García, A, Juan, A, Guardiola, J, Mínguez, M, Calvet, X, Márquez, L, Fernández Salazar, L I, Bujanda, L, García, C, Zabana, Y, Lorente, R, Barrio, J, Hinojosa, E, Iborra, M, Cajal, M Domínguez, Van Domselaar, M, García-Sepulcre, M F, Gomollón, F, Piqueras, M, Alcaín, G, García-Sánchez, V, Panés, J, Domènech, E, García-Esquinas, E, Rodríguez-Artalejo, F, Gisbert, J P

“…The objective of this study was (a) To know the prevalence and distribution of extracolonic cancer (EC) in patients with inflammatory bowel disease (IBD); (b)…”
Get full text

Increased Prevalence of Rare Sucrase-isomaltase Pathogenic Variants in Irritable Bowel Syndrome Patients by Garcia-Etxebarria, Koldo, Zheng, Tenghao, Bonfiglio, Ferdinando, Bujanda, Luis, Dlugosz, Aldona, Lindberg, Greger, Schmidt, Peter T., Karling, Pontus, Ohlsson, Bodil, Simren, Magnus, Walter, Susanna, Nardone, Gerardo, Cuomo, Rosario, Usai-Satta, Paolo, Galeazzi, Francesca, Neri, Matteo, Portincasa, Piero, Bellini, Massimo, Barbara, Giovanni, Jonkers, Daisy, Eswaran, Shanti, Chey, William D., Kashyap, Purna, Chang, Lin, Mayer, Emeran A., Wouters, Mira M., Boeckxstaens, Guy, Camilleri, Michael, Franke, Andre, D’Amato, Mauro

“…Patients with irritable bowel syndrome (IBS) often associate their symptoms to certain foods. In congenital sucrase-isomaltase deficiency (CSID), recessive…”
Get full text

Usefulness of antimicrobial susceptibility in the eradication of Helicobacter pylori by Cosme, A., Montes, M., Martos, M., Gil, I., Mendarte, U., Salicio, Y., Piñeiro, L., Recasens, M.T., Ibarra, B., Sarasqueta, C., Bujanda, L.

“…The rate of eradication of Helicobacter pylori with standard triple therapy using omeprazole, amoxicillin and clarithromycin (OAC) is unacceptable in…”
Get full text

Prevalence and Factors Associated With Fatigue in Patients With Inflammatory Bowel Disease: A Multicentre Study by Chavarría, C, Casanova, M J, Chaparro, M, Barreiro-de Acosta, M, Ezquiaga, E, Bujanda, L, Rivero, M, Argüelles-Arias, F, Martín-Arranz, M D, Martínez-Montiel, M P, Valls, M, Ferreiro-Iglesias, R, Llaó, J, Moraleja-Yudego, I, Casellas, F, Antolín-Melero, B, Cortés, X, Plaza, R, Pineda, J R, Navarro-Llavat, M, García-López, S, Robledo-Andrés, P, Marín-Jiménez, I, García-Sánchez, V, Merino, O, Algaba, A, Arribas-López, M R, Banales, J M, Castro, B, Castro-Laria, L, Honrubia, R, Almela, P, Gisbert, J P

“…The aims of this study were to determine the prevalence of fatigue in patients with inflammatory bowel disease [IBD], to identify the factors associated with…”
Get full text

Liver dysfunction related to hepatitis B and C in patients with inflammatory bowel disease treated with immunosuppressive therapy by Loras, C, Gisbert, J P, Mínguez, M, Merino, O, Bujanda, L, Saro, C, Domenech, E, Barrio, J, Andreu, M, Ordás, I, Vida, L, Bastida, G, González-Huix, F, Piqueras, M, Ginard, D, Calvet, X, Gutiérrez, A, Abad, A, Torres, M, Panés, J, Chaparro, M, Pascual, I, Rodriguez-Carballeira, M, Fernández-Bañares, F, Viver, J M, Esteve, M

“…There is no information about the frequency of liver dysfunction in patients with inflammatory bowel disease (IBD) treated with immunosuppressants and infected…”
Get more information

Diagnostic accuracy of the faecal immunochemical test for colorectal cancer in symptomatic patients: comparison with NICE and SIGN referral criteria by Cubiella, J., Salve, M., Díaz-Ondina, M., Vega, P., Alves, M. T., Iglesias, F., Sánchez, E., Macía, P., Blanco, I., Bujanda, L., Fernández-Seara, J.

“…Aim The diagnostic accuracy of the faecal immunochemical test (FIT) at a 100 ng/ml threshold for colorectal cancer (CRC) was compared with National Institute…”
Get full text

Clinical practice guidelines: quality of colonoscopy in colorectal cancer screening by Jover, R, Herráiz, M, Alarcón, O, Brullet, E, Bujanda, L, Bustamante, M, Campo, R, Carreño, R, Castells, A, Cubiella, J, García-Iglesias, P, Hervás, A J, Menchén, P, Ono, A, Panadés, A, Parra-Blanco, A, Pellisé, M, Ponce, M, Quintero, E, Reñé, J M, Sánchez del Río, A, Seoane, A, Serradesanferm, A, Soriano Izquierdo, A, Vázquez Sequeiros, E

Get more information

The changing face of hospitalisation due to gastrointestinal bleeding and perforation by Lanas, A., García‐Rodríguez, L. A., Polo‐Tomás, M., Ponce, M., Quintero, E., Perez‐Aisa, M. A., Gisbert, J. P., Bujanda, L., Castro, M., Muñoz, M., Del‐Pino, M. D., Garcia, S., Calvet, X.

“…Aliment Pharmacol Ther 2011; 33: 585–591 Summary Background  Temporal changes in the incidence of cause‐specific gastrointestinal (GI) complications may be one…”
Get full text

A GWAS meta‐analysis from 5 population‐based cohorts implicates ion channel genes in the pathogenesis of irritable bowel syndrome by Bonfiglio, F., Henström, M., Nag, A., Hadizadeh, F., Zheng, T., Cenit, M. C., Tigchelaar, E., Williams, F., Reznichenko, A., Ek, W. E., Rivera, N. V., Homuth, G., Aghdassi, A. A., Kacprowski, T., Männikkö, M., Karhunen, V., Bujanda, L., Rafter, J., Wijmenga, C., Ronkainen, J., Hysi, P., Zhernakova, A., D'Amato, M.

“…Background Irritable bowel syndrome (IBS) shows genetic predisposition, however, large‐scale, powered gene mapping studies are lacking. We sought to exploit…”
Get full text

New Advances in Polycystic Liver Diseases by Santos-Laso, A, Izquierdo-Sánchez, L, Lee-Law, P Y, Perugorria, M J, Marzioni, M, Marin, J J G, Bujanda, L, Banales, J M

“…Polycystic liver diseases (PLDs) include a heterogeneous group of congenital disorders inherited as dominant or recessive genetic traits; they are manifested…”
Get more information

Real-world use of mycophenolate mofetil in inflammatory bowel disease: Results from the ENEIDA registry by Hernández-Camba, A., Arranz, L., Vera, I., Carpio, D., Calafat, M., Lucendo, A.J., Taxonera, C., Marín, S., Garcia, M.J., Marín, G. Suris, Rodríguez, E. Sánchez, Carbajo, A.Y., De Castro, M.L., Iborra, M., Martin-Cardona, A., Rodríguez-Lago, I., Busquets, D., Bertoletti, F., Ausín, M. Sierra, Tardillo, C., Malaves, J. Huguet, Bujanda, L., Castaño, A., Domènech, E., Ramos, L., Merino, O.

“…Studies to evaluate the use of mycophenolate mofetil (MMF) in inflammatory bowel disease (IBD) are limited after the appearance of biological treatments. Our…”
Get full text

Mismatch repair status in the prediction of benefit from adjuvant fluorouracil chemotherapy in colorectal cancer by Jover, R, Zapater, P, Castells, A, Llor, X, Andreu, M, Cubiella, J, Piñol, V, Xicola, R M, Bujanda, L, Reñé, J M, Clofent, J, Bessa, X, Morillas, J D, Nicolás-Pérez, D, Payá, A, Alenda, C

“…Aim: Some retrospective studies have shown a lack of benefit of 5-fluorouracil (5-FU) adjuvant chemotherapy in patients with mismatch repair (MMR) deficient…”
Get full text

Several statins increase body and liver fat accumulation in a model of metabolic syndrome by Aguirre, L, Hijona, E, Macarulla, M T, Gracia, A, Larrechi, I, Bujanda, L, Hijona, L, Portillo, M P

“…Statins are a family of drugs used in hypercholesterolemia. The aim of this study was to analyze the effect of statins on body and liver fat accumulation in…”
Get more information